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problem.The increased expression of: (a) ER and PgR (70–75% of all
cases of breast cancer) is an indication for hormone therapy,
which is one of the simplest and most effective methods of
systemic treatment of breast cancer; (b) receptor HER2/neu is a
marker of highly aggressive form of breast cancer and indication
for the use of targeted therapy Gertseptin; (c) proliferative factor
Ki-67 reflects the ability of a tumor to metastasize.
Today, the ‘‘gold standard” of gene expression diagnostic of ER,
PgR, HER2/neu and Ki-67 in breast cancer is immunohistochem-
istry (IHC) using foreign test systems (Ventana, Dako Inc, USA) .
However, IHC diagnostics has some significant drawbacks. It
leads up to 15–17% of cases of incorrect choice of drug therapy,
which based on incorrect results of IHC studies. As a result, the
significant group of patients do not receive effective treatment.
Aim of the study Aim: the development a prototype of diagnostic
test system for detection the receptor status of breast cancer,
based on RT-PCR.
Materials and methods: Breast cancersamples consisted of 45
fresh-frozen tissue (FFT) samples of breast cancer (sites of malig-
nant transformation and normal tissue from the same patients)
and 59 FFPET sampleswere collected. All the samples had the
IHC characteristic of receptor status of ER, PgR, HER2/neu and
proliferation factor Ki-67 (Dako Inc., USA). Samples were submit-
ted by SBIH NR ‘‘Novosibirsk Regional Oncology Center” (Novosi-
birsk, Russia). The experimental part of the study was divided
into several stages: separation of mRNA from cells, obtaining
cDNA (reverse transcription reaction), PCR in real-time and vali-
dation of the test system. Isolation of total RNA from FFT samples
was performed using a set of ‘‘SV Total RNA Isolation system”
according to the manufacturer’s instructions (Promega, USA). Iso-
lation of total RNA from FFPET samples was performed using a set
‘‘ReliaPrep FFPE Total RNA Miniprep System” (Promega, USA)
according to the manufacturer’s instructions. The concentration
of total RNA was determined using a NanoDrop 1000 microspec-
trophotometer (Thermo Bioscience, USA) (RNA concentration
were 15–660 ng/ml).
Results: For the reverse transcription reaction (RT) and PCR,
the main parameters were selected. For RT: RNA incubation time
and temperature of the reaction, enzyme concentration in the
reaction mix. For PCR: the amount of DNA template, the number
of primers, the concentration of magny ions, the concentration of
the polymerase. Validation of the developed test system was car-
ried out by comparing the results obtained by RT-PCR with the
results of the IHC analysis of the same samples. Statistical pro-
cessing of the research results was performed using the MedCalc
program v.14.12.0 (Microsoft Corp.).
Conclusion: We have considered modern advanced methods of
diagnostic of breast cancer receptor status. It was concluded that
the use of RT-PCR in real time technology is the best alternative
technology of the IHC, which currently is the standard definition
of the expression of ER, PgR, HER2/neu and Ki-67. Prototype of test
system for the detection of ER, PgR, HER2/neu and Ki67 prolifera-
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Glucocorticoids (GCs) are widely used in treatment of many
cancer types due to its ability to induce apoptosis in malignant
cells in blood cancer therapy, and to prevent nausea, emesis
and chemotherapy-associated hepatotoxicity in case of solid
tumors. However, severe dose-limiting side effects occur, includ-
ing osteoporosis, diabetes and other metabolic complications.
Moreover, in therapy of solid tumors GCs strongly affect microen-
vironment which could be associated with poor prognosis, risk of
metastasis and high frequency of relapses.
Biological response to GCs is mediated by glucocorticoid
receptor (GR), a well-characterized transcription factor. GR
controls gene expression via (1) transactivation, which requires
binding of GR homodimers to glucocorticoid-responsive elements
(GRE) in gene promoters and enhancers, and (2) dimerization-
independent transrepression mediated via negative interaction
between GR and other transcription factors including major effec-
tors of inflammation and proliferation. Transrepression plays an
important role in anti-inflammatory and anti-cancer effects of
GR, including normalizing influence on microenvironment, while
side effects are associated with GR transactivation. In particular,
GCs induce insulin resistance in adipocytes, a major component
of the mammary microenvironment, which secrete pro-
inflammatory cytokines and growth factors, implicated in tumor
progression. Selective GR agonists (SEGRA) that preferentially
activate GR transrepression could be a better option for treatment
of cancer.
Dozens of candidate SEGRAs were identified, synthesized and
tested by industry and academia, with some having reached clin-
ical trials. One of the novel GR modulators is 2-(4-acetoxyphenyl)-
2-chloro-N-methylethylammonium-chloride, or CpdA, synthetic
analogue of aziridine precursor isolated from Namibian shrub
Salsola tuberculatiformis Botschantzev. It was shown that CpdA
acts as ‘‘dissociated” GR ligand: it competes with GCs for GR
binding and efficiently induces GR transrepression but not
transactivation. We and other authors reported recently that
CpdA inhibits survival of prostate cancer cells as well as blood
cancer cells in GR-dependent fashion. Furthermore, primary leu-
kemia cells from T-ALL patients appeared to be equally sensitive
to GCs and CpdA.
Our further studies were concentrated on three directions:
(1) GC/SEGRA-based chemotherapy. We screened biological
effect of CpdA in combination with traditional agents
(doxorubicin, vincristine) and newer therapeutics (Bortezomib,
Carfilzomib, MLN-4924, Rapamycin). Pretreatment of lymphoma
cells with proteasome inhibitor Bortezomib resulted in GR
accumulation and enhanced ligand properties of CpdA. We also
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revealed remarkable GR-dependent cooperation between CpdA
and Bortezomib in suppressing survival of lymphoma cells
in vitro and in vivo. Also surprising findings were substantial
cooperation in anti-cancer effect of immunosuppressant Rapa-
mycin and CpdA in vitro, and unexpected ‘‘dissociated” effect of
Rapamycin on GR signaling realized through down -regulation
of REDD1, mTORC1 inhibitor. These data suggested high clinical
potential of Rapamycin/GC combination in cancer treatment.
(2) SEGRA list extention
We used two approaches to extend SEGRA list: (1) synthesis of
CpdA enantiomers and (2) its chemical derivatives. Chemical
analogues of CpdA were designed by appending of bulky sub-
stituent into benzene ring, alkylation of carbon atom adjacent
to chlorine atom or appending of substituents to nitrogen atom.
Evaluation of biological properties of enantiomers revealed
higher GR-dependent anti-cancer potential of S-CpdA. Cytotoxic
and proapoptotic effects of CpdA analogues were comparable
with precursor.
(3) Selection of tumor types acceptable for SEGRA treatment.
CpdAwas selected for NCI-60 in Vitro Cell Line Screening Pro-
ject providing direct support to anticancer drug discovery pro-
gram. It was shown that CpdA affect viability of some adherent
cancer cell lines. We demonstrated that CpdA unlike GCs did
not modify microenvironment and disintegrate tight junctions
between cells decreasing risk of metastasis in case of solid
tumors. It demonstrates reasonability of further investigations.
Overall, our data provide the rationale for novel therapy of
cancer based on combination of non-steroidal GR modulators
with classic and modern chemotherapeutics. Approaches to
obtain more SEGRAs were elaborated.
http://dx.doi.org/10.1016/j.ejcsup.2015.08.059
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Background: There are numerous evidences suggesting that
tumor evolution follows the laws of Darwinian evolution,
whereby individual tumor cell clones have private genetic
aberrations, including chromosomal abnormalities. The
combined effect of genetic instability and differential selective
pressures of the microenvironment and chemotherapy can result
in the creation of new tumor clones (Navin et al., 2011; Ng et al.,
2012). The aim of this study is to show breast tumor clonal evolu-
tion during neoadjuvant chemotherapy (NAC) using microarray
analysis.
Material and methods: Breast cancer patients (n = 26) with
stage IIA to IIIC (T1-4N0-3M0), were treated with NAC (FAC or
CAX regimens). DNA was extracted from 26 samples of tumor
tissue derived before or after NAC using QIAamp DNA mini Kit
(Qiagen, Germany). Copy Number Aberrations (CNA, deletions
and amplifications, or Loss and Gain, respectively) and number
of mutant clones were detected in pre- and post-NAC tumor
samples using the high density microarray platform Affymetrix
(USA) CytoScanTM HD Array. This study was approved by Tomsk
Cancer Research Institute review board.
Results: We have revealed that 19% (5/26) of patients during the
NACshowed thedecrease in thenumberofmutant clones andCNA
frequency right up to their complete elimination (genetic
regression) at one case. In 7 (27%) cases chemotherapy had no
any effect on number of mutant clones and the frequency of CNA
in tumor. In the tumors of 10 patients the elimination of some
mutant clones aswell as the formation of new cloneswith deleted
genetic material occurred under the influence of chemotherapy. 6
patients have demonstrated the appearance of new tumor clones
with gene amplificationswhich were associatedwith the develop-
ment of metastases in 83% of cases (5/6). All other patients (n = 21)
who has not acquired the new tumor clones with Gain function
mutation after NAC did not manifest distant metastasis in 5-year
follow-up (Kaplan–Meier, p = 0.00001 Log-rank test).
Conclusion: The first time evidence is presented that the for-
mation of new tumor clones may occur during the NAC. Metasta-
sis of breast cancer is associated with the appearance of new
clones with DNA amplifications. Detection of these clones allow
getting new prognostic factor in breast cancer.
The study was supported by the Russian Foundation for Basic
Research – Russia (Project 15-04-03091).
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Cutaneous melanoma is one of the most aggressive human
neoplasms that can quickly metastasize to regional lymph nodes.
Currently, prognosis is determined by measuring tumor thickness
but more reliable markers for metastatic spread are urgently
needed. It is well known that tumors require a microvasculature
development in order to grow and metastasize. Angiogenesis
and lymphangiogenesis play an important role not only in the
tumor growth, but also in the tumor metastasis. As malignancy
is a disorder of cellular growth control, the assessment of cell
proliferation rates in tumors has intuitive appeal as a prognostic
marker. One such biomarker is Ki-67, a cell cycle dependent
protein. Recent reports related to its role as a prognostic factor
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